\-\ Texto\\:\\ \ \(0\)\
\-\ non\\ contributory\ \(16\)\
\-\ followed\\ by\\ ct\\ over\\ a\\ 10\\ month\\ period\\ with\\ stability\\ over\\ time\\.\ \(0\)\
\-\ the\\ right\\ adrenal\\ gland\\ is\\ enlarged\\ and\\ demonstrates\\ a\ \(0\)\
\-\ heterogeneous\\ attenuation\\.\\ \\ a\\ foci\\ of\\ fat\\ attenuated\\ region\\ is\\ noted\\ within\\ this\\ adrenal\\ lesion\\.\\ \\ the\\ right\\ adrenal\\ gland\\ measures\\ 3\\.2cmx2\\.7cmx3\\.0cm\\.\ \(0\)\
\-\ adrenal\\ mass\\ \\-\\ considered\\ to\\ be\\ benign\\ lesion\\ with\\ stability\\ over\\ 10\\ months\\ of\\ imaging\\.\\ likely\\ myelolipoma\\ given\\ imaging\\ characteristics\\.\ \(0\)\
\-\ higher\\ on\\ list\\ despite\\ focal\\ fat\\:\\ metastases\ \(0\)\
\-\ other\\:\\ myelolipoma\\,\\ adenoma\\,\\ paraganglioma\\,\\ ganglioneuroma\\,\\ pseudotumor\ \(0\)\
\-\ post\\ op\\ day\\ \\#14\\ status\\ post\\ emergency\\ total\ \(0\)\
\-\ colectomy\\ for\\ large\\ bowel\\ obstruction\\ for\\ stage\\ iii\\ colon\\ cancer\\.\\ \\ the\\ patient\\ was\\ re\\-admitted\\ for\\ intractable\\ vomiting\\ and\\ elevated\\ white\\ blood\ \(0\)\
\-\ cell\\ count\\.\ \(16\)\
\-\ this\\ case\\,\\ as\\ originally\\ seen\\,\\ was\\ more\\ suspicious\\ for\\ metastases\\ given\\ patients\\ history\\ of\\ colon\\ ca\\.\\ however\\,\\ the\\ lesion\\ remained\\ stable\\ over\\ time\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ adrenal\\:\\ 0\\.11538352144624957\ \(0\)\
\-\ myelolipoma\\:\\ 0\\.0805723960230229\ \(0\)\
\-\ stability\\:\\ 0\\.06363289541509265\ \(0\)\
\-\ 3\\.2cmx2\\.7cmx3\\.0cm\\:\\ 0\\.058770122826443325\ \(0\)\
\-\ over\\:\\ 0\\.05801713573706567\ \(0\)\
\-\ re\\-admitted\\:\\ 0\\.05144604090198926\ \(0\)\
\-\ metastases\\:\\ 0\\.0486764326672398\ \(0\)\
\-\ gland\\:\\ 0\\.04852491588523559\ \(0\)\
\-\ colon\\:\\ 0\\.04474577213096453\ \(0\)\
\-\ intractable\\:\\ 0\\.04220407849452332\ \(0\)\
\-\ attenuated\\:\\ 0\\.04167046044336641\ \(0\)\
\-\ ganglioneuroma\\:\\ 0\\.04028619801151145\ \(0\)\
\-\ colectomy\\:\\ 0\\.03988203386606855\ \(0\)\
\-\ given\\:\\ 0\\.03905885856688457\ \(0\)\
\-\ op\\:\\ 0\\.03847330657495383\ \(0\)\
\-\ 10\\:\\ 0\\.03840832304462547\ \(0\)\
\-\ post\\:\\ 0\\.03587780044096392\ \(0\)\
\-\ list\\:\\ 0\\.035665216807778476\ \(0\)\
\-\ paraganglioma\\:\\ 0\\.03526105266233558\ \(0\)\
\-\ lesion\\:\\ 0\\.034811104520009094\ \(0\)\
\-\ fat\\:\\ 0\\.03465216430508845\ \(0\)\
\-\ pseudotumor\\:\\ 0\\.03296211608705739\ \(0\)\
\-\ time\\:\\ 0\\.03218134969652417\ \(0\)\
\-\ originally\\:\\ 0\\.03217689584934816\ \(0\)\
\-\ remained\\:\\ 0\\.031044235604045508\ \(0\)\
\-\ contributory\\:\\ 0\\.02931118544113267\ \(0\)\
\-\ characteristics\\:\\ 0\\.028341134883324418\ \(0\)\
\-\ higher\\:\\ 0\\.027936970737881515\ \(0\)\
\-\ suspicious\\:\\ 0\\.02743358705449388\ \(0\)\
\-\ iii\\:\\ 0\\.026743315861554946\ \(0\)\
\-\ imaging\\:\\ 0\\.026694317659408037\ \(0\)\
\-\ period\\:\\ 0\\.02663491238907641\ \(0\)\
\-\ ca\\:\\ 0\\.026528243446766804\ \(0\)\
\-\ despite\\:\\ 0\\.026475542250052716\ \(0\)\
\-\ 14\\:\\ 0\\.02510441611144641\ \(0\)\
\-\ count\\:\\ 0\\.02477101330761533\ \(0\)\
\-\ total\\:\\ 0\\.024531466579441576\ \(0\)\
\-\ foci\\:\\ 0\\.024453492981020303\ \(0\)\
\-\ measures\\:\\ 0\\.024376420831679797\ \(0\)\
\-\ stage\\:\\ 0\\.024300229526188977\ \(0\)\
\-\ adenoma\\:\\ 0\\.023789962345373415\ \(0\)\
\-\ non\\:\\ 0\\.023548764634856733\ \(0\)\
\-\ stable\\:\\ 0\\.02348142399494671\ \(0\)\
\-\ considered\\:\\ 0\\.022996949392964313\ \(0\)\
\-\ attenuation\\:\\ 0\\.022904140469506926\ \(0\)\
\-\ \\#\\:\\ 0\\.022344577459605924\ \(0\)\
\-\ vomiting\\:\\ 0\\.021750392260299206\ \(0\)\
\-\ emergency\\:\\ 0\\.021571923986535173\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.020947967711966706\ \(0\)\
\-\ status\\:\\ 0\\.020335515474544357\ \(0\)\
\-\ obstruction\\:\\ 0\\.020089333657262905\ \(0\)\
\-\ benign\\:\\ 0\\.019660335780221343\ \(0\)\
\-\ for\\:\\ 0\\.019442883963805738\ \(0\)\
\-\ enlarged\\:\\ 0\\.019437473802560043\ \(0\)\
\-\ elevated\\:\\ 0\\.019328775742393754\ \(0\)\
\-\ followed\\:\\ 0\\.01909917247585848\ \(0\)\
\-\ white\\:\\ 0\\.018894028084746786\ \(0\)\
\-\ cancer\\:\\ 0\\.018727768429098436\ \(0\)\
\-\ day\\:\\ 0\\.018086398862352866\ \(0\)\
\-\ bowel\\:\\ 0\\.017866356885898396\ \(0\)\
\-\ month\\:\\ 0\\.017090763605337397\ \(0\)\
\-\ focal\\:\\ 0\\.016269957360922682\ \(0\)\
\-\ region\\:\\ 0\\.016090674848262085\ \(0\)\
\-\ likely\\:\\ 0\\.01606859977290438\ \(0\)\
\-\ however\\:\\ 0\\.01586245370398047\ \(0\)\
\-\ months\\:\\ 0\\.015559608631267116\ \(0\)\
\-\ blood\\:\\ 0\\.015549407150061997\ \(0\)\
\-\ cell\\:\\ 0\\.015388271410543242\ \(0\)\
\-\ \\:\\:\\ 0\\.015070330879875535\ \(0\)\
\-\ patients\\:\\ 0\\.014743830662440173\ \(0\)\
\-\ more\\:\\ 0\\.01424784206208111\ \(0\)\
\-\ noted\\:\\ 0\\.013502807923017291\ \(0\)\
\-\ was\\:\\ 0\\.013177033629515824\ \(0\)\
\-\ other\\:\\ 0\\.013130923658016325\ \(0\)\
\-\ this\\:\\ 0\\.012815162844188441\ \(0\)\
\-\ \\,\\:\\ 0\\.012633136390806744\ \(0\)\
\-\ case\\:\\ 0\\.012463362885781806\ \(0\)\
\-\ large\\:\\ 0\\.012456949545540533\ \(0\)\
\-\ demonstrates\\:\\ 0\\.012444141344354575\ \(0\)\
\-\ \\-\\:\\ 0\\.012211523058055758\ \(0\)\
\-\ right\\:\\ 0\\.012021756121472223\ \(0\)\
\-\ seen\\:\\ 0\\.011257517433784602\ \(0\)\
\-\ within\\:\\ 0\\.010867542722573878\ \(0\)\
\-\ by\\:\\ 0\\.009485806021632499\ \(0\)\
\-\ be\\:\\ 0\\.008785044822292861\ \(0\)\
\-\ as\\:\\ 0\\.00861718337262752\ \(0\)\
\-\ ct\\:\\ 0\\.00796869102261362\ \(0\)\
\-\ a\\:\\ 0\\.007931996036372025\ \(0\)\
\-\ mass\\:\\ 0\\.00792307337965043\ \(0\)\
\-\ history\\:\\ 0\\.007868096918047223\ \(0\)\
\-\ is\\:\\ 0\\.007497210378463009\ \(0\)\
\-\ patient\\:\\ 0\\.0057106128727759204\ \(0\)\
\-\ on\\:\\ 0\\.004825940082436187\ \(0\)\
\-\ the\\:\\ 0\\.003686647592096688\ \(0\)\
\-\ to\\:\\ 0\\.002847120722953242\ \(0\)\
\-\ and\\:\\ 0\\.0024001200764295796\ \(0\)\
\-\ \\.\\:\\ 0\\.002366635739823085\ \(0\)\
\-\ of\\:\\ 0\\.0023300760159597686\ \(0\)\
\-\ with\\:\\ 0\\.00156005568119853\ \(0\)\
